Lupin receives FDA nod for generic Rydapt
Midostaurin Capsules are indicated to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia.
Lupin has received approval from the Food and Drug Administration for Midostaurin Capsules, 25 mg, which is a generic of Novartis’ Rydapt.
Midostaurin Capsules, 25 mg, are indicated to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia.
[Read more: Lupin receives FDA nod for 3 generics]
Midostaurin Capsules had a market value of roughly $75 million, per IQVIA March 2024 data.